The persistence of p190 BCR-ABL transcripts is associated with lower probability of molecular response to imatinib in early and late chronic phase CML patients.

被引：0
|
作者：
Garuti, A
Ibatici, A
Cirmena, G
Miglino, M
Varaldo, R
Nicoletta, C
Grasso, R
Pozzi, S
Podesta, M
Gobbi, M
Sessarego, M
Patrone, F
Frassoni, F
机构：
[1] Osped San Martino Genova, Dept HematoOncol, Ctr Cellule Staminali & Terapia Cellulare, Genoa, Italy
[2] Osped San Martino Genova, Dipartimento Med Interna, Genoa, Italy
[3] Osped San Martino Genova, Clin Ematol, Genoa, Italy
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
10.1182/blood.V106.11.3282.3282
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3282
引用
收藏
页码：917A / 918A
页数：2
相关论文
共 50 条
  • [1] P190 BCR-ABL IS ASSOCIATED WITH INFERIOR OUTCOME IN CHRONIC MYELOID LEUKEMIA
    Chaker, F.
    Ben Said, M.
    Jeddi, R.
    Ben Amor, R.
    Ben Romdhane, N.
    Menif, S.
    HAEMATOLOGICA, 2012, 97 : 532 - 532
  • [2] INDIVIDUAL EARLY DYNAMICS OF BCR-ABL TRANSCRIPTS, BUT NOT BCR-ABL TRANSCRIPT LEVELS AT BASELINE PREDICT SURVIVAL IN PATIENTS WITH CHRONIC PHASE CML
    Shlyakhto, V.
    Hanfstein, B.
    Lauseker, M.
    Erben, P.
    Saussele, S.
    Fabarius, A.
    Proetel, U.
    Schnittger, S.
    Kolb, H.
    Krause, S.
    Schubert, J.
    Einsele, H.
    Haenel, M.
    Dengler, J.
    Falge, C.
    Kanz, L.
    Neubauer, A.
    Kneba, M.
    Stegelmann, F.
    Pfreundschuh, M.
    Waller, C.
    Spiekermann, K.
    Baerlocher, G.
    Pfirrmann, M.
    Hasford, J.
    Hofmann, W.
    Hehlmann, R.
    Hochhaus, A.
    Mueller, M.
    HAEMATOLOGICA, 2013, 98 : 453 - 454
  • [3] Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients.
    Goh, Hyun-Gyung
    Kim, Dongho
    Choi, Soo-Young
    Kim, Soo-Hyun
    Lee, Jeong
    Lee, Young-Seok
    Oh, Sang-Mi
    Kim, Dong-Wook
    BLOOD, 2010, 116 (21) : 530 - 531
  • [4] P190(BCR-ABL) CHRONIC MYELOID-LEUKEMIA (CML) - THE MISSING LINK WITH CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
    MELO, JV
    MYINT, H
    GALTON, DAG
    GOLDMAN, JM
    BLOOD, 1993, 82 (10) : A554 - A554
  • [5] Coexistence of P190 and P210 BCR/ABL transcripts in chronic myeloid leukemia blast crisis resistant to imatinib
    Zhao Junmei
    Yu Fengkuan
    Song Yongping
    Fang Baijun
    Liu Yuzhang
    Liu Lina
    Zhang Qinglan
    SPRINGERPLUS, 2015, 4
  • [6] Hasford score correlates with the dynamics of imatinib induced reduction of BCR-ABL transcripts in chronic phase CML.
    Raanani, P
    Ben-Bassat, I
    Itskovich, S
    Gan, S
    Morgulis, Y
    Kneller, A
    Brok-Simoni, F
    Rechavi, G
    Amariglio, N
    Nagler, A
    BLOOD, 2003, 102 (11) : 314B - 314B
  • [7] IMATINIB THERAPY RESPONSE IN CML PATIENTS WITH DIFFERENT BCR/ABL P210 TRANSCRIPTS
    Dmytrenko, I.
    Dyagil, I.
    Minchenko, J.
    Fedorenko, V.
    Shliakhtychenko, T.
    HAEMATOLOGICA, 2013, 98 : 562 - 562
  • [8] Decreasing BCR-ABL level in contrast to the BCR-ABL load at the start of treatment, is significantly associated with the cytogenetic response to imatinib in chronic myelogenous leukemia patients.
    Colombat, M
    Chollet, C
    Fort, MP
    Barthe, C
    Leguay, T
    Bilhou-Nabera, C
    Reiffers, J
    Marit, G
    Mahon, FX
    BLOOD, 2002, 100 (11) : 319B - 319B
  • [9] Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts
    Sharma, Pratibha
    Kumar, Lalit
    Mohanty, Sujata
    Kochupillai, Vinod
    ANNALS OF HEMATOLOGY, 2010, 89 (03) : 241 - 247
  • [10] LOW-LEVELS OF P190 BCR-ABL MESSENGER-RNA ARE DETECTABLE IN PATIENTS WITH CHRONIC PHASE P210 CML AND P210 ALL
    VANRHEE, F
    HOCHHAUS, A
    LIN, F
    GOLDMAN, JM
    CROSS, NCP
    EXPERIMENTAL HEMATOLOGY, 1995, 23 (08) : 922 - 922
12345